PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1114726
PUBLISHER: Mellalta Meets LLP | PRODUCT CODE: 1114726
The Metastatic Ovarian Cancer (mOC) market is relatively large with highest market share holding drugs in 2022 i.e., Olaparib and Niraparib. By 2032, the market is expected to change due to the loss of patents of the current therapies and the uptake and launch of new therapies. In a mOC treatment setting, the Olaparib will consistently perform and will grasp the highest market share followed by other emerging drugs. The sales of the emerging therapies for the treatment of mOC in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 5.3 billion by 2032.
"There has been constant debate among oncologists about how much treatment is too much. Ovarian cancer frequently develops in older women. We often wonder if we should offer our older patients aggressive treatment modalities such as cytoreduction and HIPEC, if the treatment is effective in these women, and if older women have more complications after these complex treatments. Our study suggests that the longevity of patients undergoing cytoreduction plus HIPEC for ovarian cancer was similar regardless of age, and older women were able to recover well from this aggressive treatment."
Ovarian cancer (OC) is the most common cancer in females worldwide and has a high mortality rate. Around 290,000 new OC cases (3.4% of all new cancer cases in females) have been diagnosed annually. Although the 5-year survival rate for ovarian cancer has improved significantly in the past 30 years, the prognosis for ovarian cancer remains poor overall, with a 48.6% 5-year relative survival rate. The prognosis of ovarian cancer is closely related to the stage at diagnosis, as determined according to the staging system developed by the International Federation of Gynecology and Obstetrics (FIGO). Approximately 20%, 5%, 58%, and 17% of women present with stage I, II, III, and IV, respectively. 60% of all cases of ovarian cancer are diagnosed when they are Stage 3. The incidence of ovarian cancer over the lifespan increases from around age 35 to a peak between 55 and 64 years of age.
The total metastatic OC (mOC) incident cases in the G7 countries are anticipated to decline to 42,940 cases by 2032 for the study period (2018- 2032). As per estimates, the United States accounted for the highest incidence of Metastatic Ovarian Cancer (mOC) cases in 2018 which was 18,793 cases and is expected to decline by 2032 for the study period. Among the EU5, Germany had the highest Metastatic Ovarian Cancer (mOC) cases, followed by Italy, France, the UK, and Spain. Japan is reported to have the highest number of cases after the United States.
All the patient's suffering from aOC will initially have the first line of therapy. However, many patients do not respond well to the first line of treatment and proceed to the second line of therapy. According to the study by Daniel C. Beachler et.al. 2020, approximately 64 percent of patients who progress following first-line therapy go on to receive a second-line. The patients who will not respond to the second line of therapy will be further treated with the third line of therapy. Approximately 45% of the patients will progress to 3L and 30% of the patients treated with 3L therapy do not respond to it and progress to 4L of therapy.
The metastatic Ovarian Cancer (mOC) therapeutics market is expected to experience high growth throughout our study period (i.e. 2018 to 2032) to USD 9.1 billion, representing compound annual growth (CAGR) of 12.8%.
The United States captured the highest market share in 2022 as compared to European 5 countries and Japan. We expect that with the launch of the new therapies, the current treatment landscape will grow, catering to the need of the metastatic patient group in all lines. By 2032, the market share of the United States is expected to increase to USD 4.6 billion whereas European 5 countries and Japan will have USD XX billion and USD XX billion market size in 2032 respectively.
Based on the patient's response to first-line platinum chemotherapy, they are classified as platinum-sensitive (response then relapse after 6-12 months), platinum-resistant (response then relapse within 6-12 months), and platinum-refractory (no response or disease progression after platinum chemotherapy). We expect about 11,000 patients will become platinum- resistant to the first line therapy.
Despite this recent advancement in the treatment landscape of advanced ovarian cancer, there is considerable overlap in the treatment paradigms for patients with newly diagnosed ovarian cancer and recurrent ovarian cancer. Experts believe that though some patients may develop platinum-resistant ovarian cancer, defined as progression within 6 months of their last treatment with platinum-based chemotherapy, it is possible to utilize platinum again if there was a response. When treating a patient who could respond to platinum-based chemotherapy, options include a carboplatin doublet with or without bevacizumab (Avastin). Typical doublets with bevacizumab may include carboplatin/paclitaxel or carboplatin/gemcitabine.
In the 2018-2032 forecast period, we expect a greater uptake of the new therapies specifically in platinum-resistant ovarian cancer (PROC). The emerging therapies which are expected to enter the market from 2022-2032 period are Mirvetuximab soravtansine/ (ImmunoGen), Ofra-vec (VBL Therapeutics), Upifitimab rilsodotin (Mersana Therapeutics), Batiraxcept (Aravive, Inc.), Navicixizumab (OncXerna Therapeutics), Alpelisib (Novartis Oncology) Cediranib (AstraZeneca), Atezolizumab (Genentech), Relacorilant (Corcept Therapeutics), Oregovomab (OncoQuest Pharmaceuticals Inc.), Olvi-Vec (Genelux Corporation), Catequentinib (Advenchen Laboratories/Jiangsu Chia Tai TianqingPharmaceutical), Stenoparib (Allarity Therapeutics), Nemvaleukin Alfa (Alkermes, Inc.), Pembrolizumab (Merck & Co) and Veliparib (AbbVie).